This activity is sponsored by the Discovery Institute of
Medical Education.

DIME

 

This activity is supported by an educational grant from GlaxoSmithKline.

GSK

INTRODUCTION

This free CME activity is based on a dinner symposium held in San Diego, California, on February 14, 2007. The Discovery Institute of Medical Education (DIME) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. DIME designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credit™.

Persons in attendance at the dinner symposium are NOT eligible for AMA PRA Category 1 Credit™ for completing this enduring material. Please note that the course is certified only for physicians (MD, DO, or equivalent). All other participants receive a certificate of completion.

In accordance with the ACCME Essential Areas and Policies regarding commercial support, participants are advised that one or more presentations in this CME activity may contain references to off-label or unapproved uses of drugs or devices. Participants should note that the use of these agents outside current approved labeling is considered experimental and are advised to consult prescribing information for these products. This CME activity was planned and produced in accordance with the ACCME Essential Areas and Policies.

Intended Audience

This CME activity is designed for orthopaedic surgeons in practice and training.

Release Date

July 25, 2007

Expiration Date

July 25, 2008

Term of Offering

This CME activity has a release date of July 25, 2007, and is valid for 1 year. Requests for credit must be received no later than July 25, 2008. After reviewing the presentation and completing the test and course evaluation, participants will receive further instruction regarding instantaneous online receipt of credit. A minimum score of 70% is required on the test for credit to be awarded. For inquiries regarding technical issues or registration, please email CME/CE Support. Please direct CME content–related questions to DIME at 212-448-5608 or dimeinfo@dimeded.org.

Chairperson

Louis M. Kwong, MD, FACS
Vice Chairman
Chief, Orthopaedic Arthritis Service
Department of Orthopaedic Surgery
Harbor-UCLA Medical Center
Torrance, California
Associate Professor of Orthopaedic Surgery
David Geffen School of Medicine at UCLA
Los Angeles, California

Faculty

Clifford W. Colwell, Jr, MD
Director
Shiley Center for Orthopaedic Research & Education
Scripps Clinic
La Jolla, California
Clinical Professor
Department of Orthopaedics and Rehabilitation
University of California San Diego School of Medicine
San Diego, California

Estimated Completion Time

1 hour

Learning Objectives

Upon completion of this course, participants should be able to

  • understand the potential morbidity from the nonfatal sequelae of VTE,
  • synthesize information regarding porous tantalum and its application to orthopaedic reconstruction, and
  • develop a clear understanding of the guidelines rendered by the International Surgical Thrombosis Forum (ISTF) and the American College of Chest Physicians regarding VTE prophylaxis following major orthopaedic surgery.

Accreditation and Designation of Credit

DIME is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

DIME designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Disclosure Policy

DIME requires that those involved with content development and/or presentation disclose to participants any significant financial interest or other relationship with (1) the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) any commercial supporters of the activity.

Off-label Discussion

This CME activity may include discussions regarding the use of medications that may be outside the approved labeling for these products. Physicians should consult the current prescribing information for these products. DIME requires the speaker to disclose that the product is not labeled for the use under discussion. Compliance is documentation that demonstrates the provider has a practice in place to make this requirement known to the faculty.

Faculty Disclosures

Louis M. Kwong, MD, FACS
Sources of Funding for Research: Bayer HealthCare; GlaxoSmithKline; Pfizer Inc; sanofi-aventis Group.
Consulting Agreements: Zimmer, Inc.
Speakers Bureau/Honorarium Agreements: None.
Financial Interests/Stock Ownership: None.
Discussion of Off-label, Investigational, or Experimental Drug Use: Porous tantalum application in soft tissue reattachment.

Clifford W. Colwell, Jr, MD
Sources of Funding for Research: AstraZeneca Pharmaceuticals LP; Bayer Healthcare; Boehringer Ingelheim Pharmaceuticals, Inc; Pharmacia Corporation; sanofi-aventis Group.
Consulting Agreements: None.
Speakers Bureau/Honorarium Agreements: None.
Financial Interests/Stock Ownership: None.
Discussion of Off-label, Investigational, or Experimental Drug Use: None.

Instructions to Participants

Course participants must view the entire presentation, take the course test, and complete the course evaluation to receive CME credit. A minimum score of 70% is required on the test for credit to be awarded. No fees are charged to participate in the activity or to receive the certificate. Full instructions are available on the user instructions page.

Disclaimer

The opinions expressed herein are those of the faculty and do not necessarily represent the views of the grantor, accrediting body, or publisher. Please review complete prescribing information of specific drugs or combinations of drugs, including indications, contraindications, warnings, and adverse effects, before administering pharmacologic therapy to patients.

Medicine is a constantly changing science, and clearly established therapies are not always available for every condition. New research findings necessitate continual changes in drug and treatment therapies. Reasonable efforts have been made to provide up-to-date, accurate information that is within generally accepted medical standards at the time of publication. However, as medical science is ever evolving, and human error is always possible, the educational supporter, provider, and publisher (or any other involved party) do not guarantee total accuracy or comprehensiveness of the information in this article, and they are not responsible for omissions or errors or for the results of using information provided in this course. Participants should confirm the accuracy of the information in this activity from other sources. In particular, all drug doses, indications, and contraindications should be confirmed in package inserts.

Click here to view minimum system requirements.